Physician profile
Bryan C Ding
NPI 1306003975
$2,576.65
in general payments reported to CMS, 2019-2025
15 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $72.88 · 2021: $22.09 · 2022: $718 · 2023: $314 · 2024: $161 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,481.12 | 2022-2025 | Inbone, Augment Injectable, Infinity |
| Nevro Corp. | $163.53 | 2022 | |
| Lifenet Health | $133.65 | 2025 | Quadlink, Duallink, Graftlink |
| Royal Biologics, INC. | $132.61 | 2019 | |
| In2bones USA, LLC | $129.56 | 2019 | |
| Depuy Synthes Sales INC. | $92.88 | 2022-2025 | Monovisc, Orthovisc |
| Horizon Therapeutics Plc | $76.05 | 2019 | |
| Gotham Surgical Solutions & Devices, INC. | $74.40 | 2025 | |
| Biopro, INC. | $68.42 | 2020 | |
| Bioventus LLC | $62.31 | 2022 | |
| Axogen | $49.92 | 2023 | Avance Nerve Graft |
| Ferring Pharmaceuticals INC. | $49.22 | 2024 | Euflexxa |
| Medtronic USA, INC. | $36.43 | 2019 | |
| Integra Lifesciences Corporation | $22.09 | 2021 | |
| Orthofix Medical, INC. | $4.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.